The over-expression of EZH2 has been described in various types of cancers, including prostate, breast, bladder, gastric, lung, and hepatocellular carcinoma, which correlate with aggressive clinical manifestations [32]. This evidence concerns the gene EZH2 and hepatocellular carcinoma.